High-Dose Biotin Compositions for Optic Atrophy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions containing biotin have low doses, which are insufficient for effectively treating visual deficiencies and neurological disorders linked to optic atrophy, and there is a need for a higher dose form that can be administered orally or injectably to improve clinical outcomes without toxic effects.
Innovation Solution
Development of pharmaceutical compositions with high doses of biotin, specifically 100 mg per unit dose for oral administration and at least 20 mg per unit dose for injectable forms, as the sole active ingredient, designed to treat visual deficiencies and optic atrophy, utilizing known excipients to ensure bioavailability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If low-dose biotin compositions are used, then safety and tolerability are maintained, but therapeutic effectiveness for visual deficiencies and optic atrophy is insufficient
Solution Approach 1:
The patent applies parameter changes by dramatically increasing the biotin dose from conventional low doses (typically <1mg) to high doses (10-100mg per unit dose). This parameter change resolves the contradiction by demonstrating that high doses achieve therapeutic effectiveness for visual deficiencies and optic atrophy while maintaining safety and tolerability, as evidenced by clinical improvement in patients without toxic effects.
2Reliability
If high-dose biotin compositions are developed, then therapeutic effectiveness for visual deficiencies is improved, but formulation complexity and manufacturing challenges increase
Solution Approach 1:
The patent applies segmentation by providing multiple formulation options with different biotin concentrations (10mg, 50mg, 100mg per unit dose) and different administration routes (oral, injectable). This allows clinicians to segment the treatment approach based on patient needs, resolving the contradiction by offering simplified formulations for routine use while maintaining the option for more complex formulations when needed.
Solution Approach 2:
The patent applies universality by developing biotin compositions that can serve multiple functions: oral administration for maintenance therapy, injectable forms for acute treatment, and various dosage strengths for different clinical scenarios. This multi-functionality resolves the contradiction by creating a universal treatment platform that addresses visual deficiencies across different severity levels without requiring entirely separate formulation systems.
3Reliability
If biotin dose is increased to treat optic atrophy, then clinical signs improve, but risk of toxic effects may increase
Solution Approach 1:
The patent applies self-service by leveraging biotin's role as a water-soluble vitamin that the body can naturally excrete in excess through urine. This physiological self-regulation mechanism resolves the contradiction by allowing high doses (10-100mg) to achieve therapeutic effectiveness for optic atrophy while the body's natural excretion pathways prevent toxic accumulation, as confirmed by the absence of toxic effects in treated patients.
Data Source
Figure 1A~2B
Figure 3A~3B
AI summary
The invention relates to novel pharmaceutical compositions highly dosed with biotin, as well as to the use thereof in treating visual impairments which are related, in particular, to optic atrophy.